IMPARP-HRD Statistical Analysis Plan

This document presents the statistical analysis plan for the study 'IMPARP-HRD', a multi-centre, signle arm, signal seeking, phase II study designed to evaluate the efficacy and safety of pamiparib and tislelizumab in patients with locally recurrent, incurable or metastatic solid cancer of any histological type.